SURGEN: 1020 H&E-STAINED WHOLE SLIDE IMAGES WITH SURVIVAL AND GENETIC MARKERS

© Craig Myles* School of Computer Science University of St Andrews cggm1@st-andrews.ac.uk In Hwa Um School of Medicine University of St Andrews ihu@st-andrews.ac.uk

David Harris-Birtill School of Computer Science University of St Andrews dcchb@st-andrews.ac.uk Craig Marshall Lothian Biorepository NHS Lothian craig.marshall@nhs.scot

David J Harrison School of Medicine University of St Andrews djh20@st-andrews.ac.uk

ABSTRACT

Background: Cancer remains one of the leading causes of morbidity and mortality worldwide. Comprehensive datasets that combine histopathological images with genetic and survival data across various tumour sites are essential for advancing computational pathology and personalised medicine. **Results**: We present SurGen, a dataset comprising 1,020 H&E-stained whole slide images (WSIs) from 843 colorectal cancer cases. The dataset includes detailed annotations for key genetic mutations (*KRAS*, *NRAS*, *BRAF*) and mismatch repair status, as well as survival data for 426 cases. To demonstrate SurGen's practical utility, we conducted a proof-of-concept machine learning experiment predicting mismatch repair status from the WSIs, achieving a test AUROC of 0.8316. These preliminary results underscore the dataset's potential to facilitate research in biomarker discovery, prognostic modelling, and advanced machine learning applications in colorectal cancer. **Conclusions**: SurGen offers a valuable resource for the scientific community, enabling studies that require high-quality WSIs linked with comprehensive clinical and genetic information on colorectal cancer. Our initial findings affirm the dataset's capacity to advance diagnostic precision and foster the development of personalised treatment strategies in colorectal oncology. Data available online: https://doi.org/10.6019/S-BIAD1285.

Keywords whole slide image (WSI) \cdot haematoxylin and eosin (H&E) stain \cdot mismatch repair (MMR) \cdot microsatellite instability (MSI) \cdot KRAS mutation \cdot NRAS mutation \cdot BRAF mutation \cdot colorectal cancer \cdot digital pathology \cdot dataset

1 Background

Colorectal cancer is among the most common and lethal cancers worldwide with over 900,000 deaths occurring each year [1, 2]. Advances in computational pathology and machine learning have the potential to revolutionise cancer diagnosis and treatment by enabling the analysis of complex histopathological and genetic data across various tumour types [3, 4].

High-quality datasets that combine whole slide images (WSIs) with detailed clinical and genetic annotations are crucial for developing and validating computational models. However, the field currently faces significant limitations due to the scarcity of publicly available, annotated datasets that integrate both imaging and non-imaging patient data [5]. Existing datasets often focus on specific cancer sites – such as breast [6–8], gastric and colorectal [9, 10], and lung [11] – or lack comprehensive annotations necessary for advanced computational pathology research. Additionally, the quality of publicly available samples can be highly variable, potentially hindering the development of robust and

^{*}Corresponding Author.

Paper under review.

generalisable models [5]. The SurGen dataset addresses these gaps by providing a diverse and high-quality collection of WSIs linked with genetic mutations, mismatch repair status, and cancer staging across colorectal and neighbouring sites. Additionally, it includes survival data specifically for the primary colorectal cancer cohort, enhancing its value for prognostic studies in this prevalent cancer type.

This article reports on the composition, collection, and potential applications of the SurGen dataset, highlighting its utility for both focused studies specific to primary colorectal cancer and broader investigations into metastatic tumour sites. This is particularly pertinent given that up to 50% of patients with localised disease eventually develop metastases [12].

The SurGen dataset is a comprehensive digital pathology resource designed to support a wide range of cancer and computational pathology research initiatives. It consists of whole slide images (WSIs) coupled with detailed clinical and genetic data, spanning colorectal regions as well as neighbouring metastatic sites. See table 2 for a breakdown of tumour sites across the SurGen dataset. The dataset is divided into two distinct subsets:

- 1. **SR386** (Colorectal Cohort with Survival Data) focuses on primary colorectal cancer, consisting of 427 WSIs from 427 cases with a focus on colorectal tumour sites. This subset includes survival data in addition to biomarker labels, such as mutation status in the *KRAS*, *NRAS*, and *BRAF* genes, as well as mismatch repair (MMR) status. This makes it particularly valuable for research aimed at understanding the genetic and biomarker properties of colorectal cancer for the exploration and prediction of its clinical outcomes.
- 2. SR1482 (Colorectal Cancer with Metastatic Sites) is a subset that contains 593 WSIs from 416 colorectal cancer cases. This cohort includes WSIs from both primary colorectal tumours and metastatic lesions in sites such as the liver, lung, peritoneum, and others. While it does not include survival data, it offers extensive biomarker information, making it valuable for studies on genetic and molecular characteristics of colorectal cancer and its metastatic behaviour.

The SurGen dataset aims to facilitate research in oncology and digital pathology by providing high-quality, labelled WSIs that can be used for training and validating computational models, investigating tumour and oncological properties, and exploring biomarker-driven stratification in colorectal cancer. This article reports on the composition, collection, and potential applications of the SurGen dataset, highlighting its utility for both focused studies on colorectal cancer and broader investigations into neighbouring metastatic sites and generalised oncological understanding.

To highlight the comprehensive nature of the SurGen dataset, we compare it with several publicly available colorectal cancer datasets. Table 1 summarises key attributes such as the inclusion of genetic markers, survival data, and tumour staging.

Table 1: Comparative overview of publicly available formalin-fixed-paraffin-embedded (FFPE) H&E stained colorectal
whole slide image datasets with relevant biomarker labels.

	0													
Dataset	Access	Origin	Cases	WSIs	Magnification	MPP	KRAS	NRAS	BRAF	MSI/MMR	Survival	Staging	Pathological	Segmentation
SurGen (Ours)	Public	GBR	843	1020	40X	0.1112	1	1	1	1	1	1	1	X
PAIP [10]	Upon Request	KOR	118	118	40X	0.2522	X	X	X	1	×	X	×	1
TCGA-COAD [13]	Public	USA	451	459	20X or 40X	*0.2436	1	1	1	1	1	1	1	X
TCGA-READ [13]	Public	USA	164	165	20X or 40X	*0.2427	1	1	1	1	1	1	1	X
CPTAC-COAD [14]	Public	USA	105	220	40X	0.2501	1	1	1	1	×	1	1	X
CRC-Orion [15]	Public	USA	40	42	20x	0.3250	1	1	1	1	1	1	1	1

Note: cases are only counted if at least one diagnostic whole slide image (WSI) is available per clinical record. Note that reported case counts may differ across publications due to varying inclusion criteria and filtering methods. This table does not include any tumour microarray (TMA) or patch-based datasets. MPP = Microns per pixel. MPP values marked with * are mean values across the cohort, with ranges: TCGA-COAD (0.2325-0.2527), TCGA-READ (0.2325-0.2520).

As shown in Table 1, the SurGen dataset provides a valuable addition to publicly available resources, uniquely integrating high-resolution WSIs with detailed genetic, clinical, and survival data. While datasets such as TCGA-COAD, TCGA-READ, and CPTAC-CRC offer comprehensive genomic sequencing data, SurGen complements these resources by focusing on key colorectal cancer biomarkers (*KRAS*, *NRAS*, *BRAF*, MSI/MMR) and survival outcomes. Moreover, its consistent high-resolution scanning at 40× magnification across all slides ensures uniform image quality, addressing variability seen in some datasets, such as TCGA.

SurGen is among the largest publicly available colorectal cancer WSI datasets, with 1,020 slides from 843 cases, exceeding the combined slide count of TCGA-COAD, TCGA-READ, and CPTAC-CRC. While SurGen's genomic annotation is focused on specific biomarkers, its scale, resolution, and inclusion of survival data make it particularly well-suited for computational pathology research, prognostic modelling, and biomarker classification in colorectal cancer.

Tumour Site	SurGen	SR386	SR1482
Rectum	276	166	110
Sigmoid Colon	142	89	53
Caecum	118	64	54
Ascending Colon	99	43	56
Transverse Colon	46	25	21
Liver	38	0	38
Descending Colon	33	16	17
Splenic Flexure	22	14	8
Hepatic Flexure	16	7	9
Peritoneum/Omentum	16	0	16
Appendix	9	1	8
Lung	4	0	4
Lymph Nodes	4	0	4
Small Bowel	3	0	3
Bladder	3	0	3 3 2
Gall Bladder	2	0	2
Pelvis	2	0	2
Site Unknown	2	2	0
Kidney	1	0	1
Throat/Vocal Cords	1	0	1
Adrenal Gland	1	0	1
Umbilical Area	1	0	1
Spine	1	0	1
Perineal Area	1	0	1
Duodenum	1	0	1
Ureter	1	0	1

Table 2: Tumour Site Counts for SurGen, SR386, and SR1482

Note: Green-shaded cells indicate tumour sites within the top cumulative ranges of approximately 90% for each respective dataset (SurGen, SR386, and SR1482). The exact highlighted cumulative totals are 91.81%, 90.63%, and 91.83%, respectively. These sites collectively account for the majority of tumour occurrences in each dataset.

2 Data Description

This section provides an overview of the SurGen dataset, which includes whole slide images (WSIs) and corresponding clinical and genetic data. The dataset is intended to support research in cancer and computational pathology, offering a resource for studying genetic mutations, mismatch repair status, and patient survival outcomes. Below is a detailed description of the data and its collection process.

Each WSI in the SurGen dataset is scanned at ×40 (0.1112 μ m per pixel) magnification, resulting in ultra-high-resolution images with pixel dimensions averaging 189,662 × 156,059 pixels. Figure 1 illustrates the spread of WSI dimensions across the SurGen dataset. The images are stored in the CZI file format, which supports hierarchical pyramidal data structures for efficient storage and retrieval. Figure 2 demonstrates the level of granularity accessible via the ultra-high-resolution WSIs.

2.1 Patient Demographic

The SurGen dataset comprises clinical information from 843 cases, with patients ranging from 19 to 97 years of age (mean age = 64.58, SD = ± 12.73), as illustrated in Figure 3. The dataset includes both male and female patients, with a slightly higher representation of males (53.97%).

2.2 Patient Survival

Survival data is available for the SR386 cohort, providing insights into patient outcomes over a five-year period following diagnosis. The dataset includes binary labels indicating whether a patient survived beyond the duration of the study, as well as the number of days until death for those who did not. For patients who outlived the study period or




Figure 1: Heatmap of WSI dimensions (in pixels) across the SurGen dataset, illustrating the variability in image sizes due to differing tissue sample areas.




Figure 2: Hierarchical zoom visualisation of case SR1482_T412 with dimensions $242,506 \times 134,026$ pixels, corresponding to $26,974.20 \times 14,907.85 \,\mu m$. A) A low-resolution macro image of the whole slide, providing full anatomical context. B) Digitised whole slide image viewed at low-magnification. C) Successive zoom-ins of the selected region from b), providing increased granularity, enabling detailed examination of tissue structures while retaining the broader context. This hierarchical approach allows comprehensive visual exploration of tissue characteristics at varying scales. In practice, the pyramid levels are typically generated via Gaussian down-sampling to simulate various levels of magnification but enable an immediate interface for retrieving images at varying resolutions.

whose survival extends beyond the recorded date, their exact number of days until death is not captured, resulting in right-censoring.




Figure 3: Illustration of the age distributions (in years) of patients in each cohort, split by sex. The width of each violin represents the density of data points at different ages, highlighting the distributions within and across the cohorts.

Within the SR386 cohort, 161 patients (38%) died during the study period, while 264 patients (62%) were alive at the end of the study period. This distribution provides a general understanding of patient outcomes in the cohort. An overview of the binarised five-year survival outcomes is presented in Figure 4. CRC was the primary cause of death in 67 out of 161 deceased patients, accounting for 41.61% of all deaths in the cohort.




Figure 4: Bar chart depicting the 5-year survival outcomes of the SR386 cohort. The chart shows the number of individuals who survived (n=264) versus those who did not survive (n=161) within the 5-year period following diagnosis. The data excludes instances where survival status was not recorded (NULL values).

To visualise the survival probabilities over time, a Kaplan-Meier survival curve was constructed for the SR386 cohort, as shown in Figure 5. This curve illustrates the proportion of patients surviving at each time point during the study period. The gradual decline in the curve represents the decreasing number of patients alive as time progresses.

For the patients who did not survive beyond the study period, we analysed the distribution of their survival times. Figure 6 presents a box plot summarising key statistics of these survival times in days. The plot shows the minimum, first quartile (Q1), median, third quartile (Q3), maximum, and mean survival times. Specifically, the median survival time was 770 days, indicating that half of the patients who died did so within this number of days post-diagnosis.

Additionally, Figure 7 displays a histogram of the survival times for patients who died within the study period. The histogram shows how many patients died within specific time intervals, providing an overview of the distribution of survival times among these patients.

Due to quality control measures, missing information, or data inconsistencies, certain cases (i.e. 004, 208, 430) have been redacted or marked as '*NULL*' with respect to survival. However, these cases remain in the dataset as they contain valuable genetic information that can be utilised for separate predictive tasks.

2.3 Genetic Mutations

The SurGen dataset includes ground truth labels for key genetic mutations in the *KRAS*, *NRAS*, and *BRAF* genes, as well as mismatch repair (MMR) status and/or microsatellite instability (MSI). Figure 8 presents the distribution of these




Figure 5: Kaplan-Meier survival curve illustrating estimated survival probabilities over time. Censoring occurred for patients who survived beyond the 5-year study duration, as they were not followed further. The curve reflects the proportion of individuals surviving at each time point, with confidence intervals representing the uncertainty in these estimates.




Figure 6: Box plot showing the distribution of survival times (in days) for cases in the SR386 cohort with recorded days till death. The plot illustrates key summary statistics, including the mean, minimum, first quartile (Q1), median, third quartile (Q3), and maximum survival times.

genetic mutations by sex. These genetic markers are crucial for understanding the molecular characteristics of tumours and their potential response to targeted therapies. Below, each mutation is discussed in detail.

BRAF Mutation: Present in 12.34% of SurGen cases, aligning with frequencies reported in the literature, which range from 3.5% to 13% [16–20]. BRAF mutations are critical in the MAPK/ERK signalling pathway and are significant targets for therapeutic intervention [21, 22].

KRAS Mutation: Present in 38.43% of SurGen cases, consistent with the range reported in other studies, from 37% to 46.4% [16–19, 23]. KRAS is a proto-oncogene involved in cell signalling pathways that regulate cell growth and death. Mutations in KRAS are often linked to resistance to specific therapies, highlighting the importance of their identification for effective treatment planning [23].

NRAS Mutation: Observed in 3.80% of SurGen cases, this falls within the range of 2.6% to 9% reported across various studies [17–20]. Like KRAS, NRAS mutations can influence treatment options and prognosis, though NRAS mutations are less common.

2.4 Mismatch Repair Deficiency and Microsatellite Instability

Mismatch repair deficiency (dMMR) and microsatellite instability (MSI) are critical genetic features in many cancers, particularly colorectal cancer [24]. dMMR occurs when the mismatch repair system, which normally corrects DNA replication errors, is compromised. This deficiency leads to an accumulation of mutations, particularly in regions of




Figure 7: Histogram showing the distribution of survival times (in days) for cases in the SR386 cohort with recorded days until death. The x-axis represents the number of days until death, and the y-axis indicates the number of individuals who died within each time interval.

repetitive DNA known as microsatellites. When these microsatellites become unstable due to dMMR, the condition is termed microsatellite instability (MSI)[24, 25].

MSI is a key biomarker used to assess cancer prognosis and predict responses to certain therapies, such as immunotherapy. Tumours exhibiting high levels of MSI (MSI-high) are often associated with a better prognosis and may respond favourably to immune checkpoint inhibitors [26, 27]. Identifying MMR and MSI status is essential for developing targeted treatment strategies and improving patient outcomes.

Importantly, dMMR and MSI are hallmark features of Lynch syndrome (LS), the most common hereditary colorectal cancer predisposition syndrome, accounting for approximately 3% of all colorectal cancers [28, 29]. LS, also known as hereditary non-polyposis colorectal cancer (HNPCC), is caused by germline mutations in the MMR genes (*MLH1*, *MSH2*, *MSH6*, and *PMS2*) [30], leading to a higher risk of developing colorectal cancer and other cancers at a younger age. Identifying patients with dMMR/MSI can therefore aid in diagnosing Lynch syndrome and facilitating genetic counselling [31].

In our study, the assessment of MMR status and MSI status differed between the SR386 and SR1482 cohorts.

2.4.1 Assessment of MMR and MSI Status in Cohorts

While the SR386 cohort reports MMR status assessed through immunohistochemistry (IHC) for key MMR proteins, the SR1482 cohort reports both MMR and MSI status.

SR386 Cohort. In the SR386 cohort, MMR status was assessed exclusively using immunohistochemistry (IHC) for two key MMR proteins; MLH1 and PMS2. Cases were labelled according to the specific loss of expression observed. Primary antibodies against MLH1 and PMS2 were applied, and loss of nuclear staining in tumour cells for any of these MMR proteins was recorded.

SR1482 Cohort. In the SR1482 cohort, MSI status was determined using either immunohistochemistry (IHC) for MMR proteins (MLH1, MSH2, MSH6, PMS2) or PCR-based fragment analysis. For the PCR-based approach, the Promega OncomateTM kit was utilised according to the manufacturer's recommended protocol. Cases were classified as MSI/dMMR if they showed evidence of microsatellite instability through PCR analysis or a loss of protein expression by IHC.

2.4.2 Mismatch Repair

Mismatch repair (MMR) status is available for most cases, with a distinction between microsatellite stable (MSS/pMMR) and microsatellite unstable (MSI/dMMR) tumours within the SR1482 dataset. This information is crucial for identifying patients who might benefit from immunotherapy [25, 26].

2.4.3 Microsatellites

Microsatellite instability (MSI) is a condition of genetic hypermutability that results from impaired DNA mismatch repair (MMR). Identifying MSI is important as it has implications for the prognosis and treatment of cancer.




Figure 8: Bar chart depicting mutation prevalence across the SurGen dataset, highlighting mutation status of patients across a) KRAS, b) NRAS, c) BRAF, and d) MSI/MMR.

2.5 Staging

Tumour staging is a critical aspect of cancer diagnosis and treatment planning, providing a framework for assessing the extent of cancer spread within the body. Staging systems help in predicting patient prognosis, guiding treatment decisions, and enabling comparisons across clinical studies and populations [32]. Two widely used staging systems in colorectal cancer are the Dukes' staging system[33] and the TNM (Tumour, Node, Metastasis) staging system[34], each offering distinct advantages and serving different clinical needs.

The Dukes' staging system is one of the earliest methods used to classify the extent of colorectal cancer. It is relatively simple and easy to apply, making it useful for broad clinical assessments. However, although it includes stages for lymph node involvement (Stage C) and distant metastasis (Stage D), its simplicity limits its ability to provide more detailed, granular information on tumour characteristics [35].

The TNM staging system, in contrast, is more detailed and widely applicable across various cancer types. It provides a comprehensive classification based on the size and extent of the primary tumour (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). This system is advantageous for its specificity and adaptability to different cancers, though it can be more complex to use compared to the Dukes' system.

These staging systems are integral to clinical guidelines, informing treatment strategies such as surgical intervention, chemotherapy, and targeted therapies based on the stage of cancer.

The SurGen dataset includes tumour staging information using both the Dukes' and TNM staging systems, which are essential for correlating clinical outcomes with tumour progression. Understanding the distribution of these stages across the cohort can offer valuable insights into the disease dynamics within the study population.

2.5.1 Tumour Staging with Dukes'

The Dukes' staging system classifies colorectal cancer into four stages (A, B, C, and D), based on the extent of tumour invasion and the presence of lymph node involvement or distant metastasis [33]. Stage A represents the earliest form of cancer, confined to the mucosa, while Stage D indicates advanced disease with distant metastasis. This system, though less detailed than TNM, provides a quick and accessible way to gauge tumour progression and patient prognosis.

2.5.2 TNM Staging

The TNM staging system is a more granular approach that classifies cancer based on three key components: the size and extent of the primary tumour (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis

(M) [36]. Each of these components is assigned a score, and the combination of these scores determines the overall stage of the cancer, ranging from Stage 0 (in situ, non-invasive cancer) to Stage IV (advanced cancer with distant metastasis).

A comprehensive summary of the SurGen including survival data, genetic mutations, and image properties for both the SR386 and SR1482 sub-cohorts is provided in Table 3.

Table 3: Overview of the SurGen dataset with respective technical, clinical, and mutational characteristic breakdown of the sub-sets SR386 and SR1482. Note: MSI/MMR ground truth was determined using Immunohistochemistry (IHC) or Polymerase Chain Reaction (PCR).

	SurGen Dataset	SR386	SR1482
Origin	Scotland	Scotland	Scotland
Number of cases	843	427	416
Number of WSIs	1020	427	593
WSI file format	.CZI	.CZI	.CZI
Magnification	40X	40X	40X
Microns per pixel (pixel width)	$0.1112 \mu m$	$0.1112 \mu m$	$0.1112 \mu m$
Mean age (std. dev.)	64.58 (±12.73)	67.89 (±12.00)	61.20 (±12.59)
Female, n (%)	388 (46.03%)	197 (46.14%)	191 (45.91%)
Male, n (%)	455 (53.97%)	230 (53.86%)	225 (54.09%)
MSI/MMR ground truth	PCR/IHC	IHC	PCR/IHC
MSI/dMMR, n (%)	79 (9.37%)	32 (7.49%)	47 (11.30%)
MSS/pMMR, n (%)	745 (88.37%)	395 (92.51%)	350 (84.13%)
MSI/MMR status unknown, n (%)	19 (2.25%)	0 (0%)	19 (4.57%)
Five year survival (true), n (%)	264 (31.32%)	264 (61.83%)	0 (0%)
Five year survival (false), n (%)	162 (19.22%)	162 (37.94%)	0 (0%)
Five year survival (unreported), n (%)	417 (49.47%)	1 (0.23%)	416 (100%)
BRAF mutation, n (%)	104 (12.34%)	47 (11.00%)	57 (13.70%)
BRAF wild type, n (%)	656 (77.82%)	379 (88.76%)	277 (66.59%)
BRAF status unknown, n (%)	83 (9.85%)	1 (0.23%)	82 (19.71%)
KRAS mutation, n (%)	324 (38.43%)	147 (34.43%)	177 (42.55)%)
KRAS wild type, n (%)	487 (57.77%)	266 (62.30%)	221 (53.12%)
KRAS status unknown, n (%)	32 (3.80%)	14 (3.26)	18 (4.33%)
NRAS mutation, n (%)	32 (3.80%)	16 (3.75%)	16 (3.85%)
NRAS wild type, n (%)	722 (85.65%)	399 (93.44%)	323 (77.64%)
NRAS status unknown, n (%)	89 (10.56%)	12 (2.81%)	77 (18.51%)

2.6 Data collection

2.6.1 Tissue Sample Preparation

Samples underwent formalin-fixed-paraffin-embedding (FFPE) processing. This involved fixing tissue specimen in formalin to preserve cellular structures and proteins, followed by embedding the samples in paraffin wax.

Once FFPE samples were prepared, they were processed using a microtome set to section at $5\mu m$ before being laid onto a glass slide. These slides were then subjected to routine haematoxylin and eosin (H&E) staining prior to their digitisation.

Slides were first immersed in haematoxylin, which stains the cell nuclei blue-purple. Following a rinse, slides were stained with eosin, which stains the cytoplasm and extracellular matrix pink. After staining, the slides underwent a dehydration process involving graded alcohols and xylene. Coverslips were subsequently applied with a mounting medium to preserve the stained sections.

2.6.2 Tissue Sample Digitisation

Prepared slides were digitised on-site using a ZEISS Axio Scan.Z1 Microscopy Slide Scanner at $40 \times$ magnification, equipped with a Plan-Apochromat 40x/0.95 Korr M27 objective lens. The scans were performed using ZEN 2.6 (blue edition) software, capturing brightfield images with controlled transmitted light illumination. Digitised images were

saved in 24-bit BGR format (BGR24) with a pixel size of $0.1112\mu m$. A multi-resolution pyramidal image structure was generated, with each subsequent layer downsampled by a factor of 2 relative to the previous layer, using Gaussian filtering to maintain image quality. Figure 9 illustrates the WSI pixel counts across the SurGen dataset.




Figure 9: Histogram illustrating the scale of SurGen whole slide images with respect to the number of pixels per image. The x-axis represents the total number of pixels in each image (in tens of billions, 1×10^{10}), while the y-axis indicates the frequency of occurrence of images within each bin. The distribution shows the variability in the sizes of whole slide images across the dataset.

2.6.3 DNA Sequencing

Next Generation Sequencing (NGS) was performed to determine the mutation status of KRAS, NRAS, and BRAF using the Ion Torrent[™] Cancer Hotspot Panel v2 (Thermo Fisher Scientific), following the manufacturer's protocol.

2.7 Data curation and quality control

To ensure the quality and reliability of the SurGen dataset, we implemented several data curation and quality control measures.

2.7.1 Slide Quality Assessment

All WSIs were reviewed by specialised laboratory personnel trained in the preparation of tissue samples for microscopic examination. Each slide was assessed for staining quality, focus, and absence of artifacts. Slides that did not meet acceptable standards were re-scanned or re-prepared to improve image quality.

2.7.2 Data Alignment and Consistency

To maintain data integrity and maximise the utility of the dataset, we carefully matched each WSI with its corresponding clinical and genetic data. WSIs without any matching clinical data were excluded from the dataset, as clinical context is essential for meaningful analyses. However, clinical data entries were retained even if some fields were incomplete, provided they had a corresponding WSI. This approach ensured that all included WSIs had associated clinical information, enhancing the dataset's applicability while acknowledging that some clinical records might have missing data points.

2.7.3 Anonymisation and Ethical Considerations

Patient confidentiality was prioritised throughout the curation of the SurGen dataset. In line with contemporary data ethics in computational pathology [5, 37], we implemented deidentification protocols to ensure privacy while maximising data utility. Recognising that medical images potentially carry the risk of re-identification when combined with external data sources, our anonymisation strategy involved the removal or redaction of potentially identifiable information, including dates of diagnosis, date of death, and treatment details.

2.8 Data use

Researchers can interact with the WSIs using tools such as OpenSlide [38], pylibCZIrw [39], and Bioformats [40]. The images are saved in a hierarchical pyramidal format, facilitating efficient viewing and processing at multiple resolutions. Software like QuPath [41], Fiji [42], ImageJ [43], and others can be used to visualise and analyse these images.

To illustrate SurGen's practical utility, we provide a simple Python example for extracting a region of interest from a whole slide image. A Python script was implemented using pylibCZIrw (Figure 10). The script illustrates the process of identifying the centre of the WSI and extracting a 2048 × 2048 pixel region of interest (ROI) at full resolution. The extracted tile (Figure 11) provides a high-resolution view from the WSI, showcasing the potential for downstream analyses or tasks, such as patch-level feature extraction or visualisation.

```
from pylibCZIrw import czi
# Path to the CZI file
path = "./SR1482_40X_HE_T232_01.czi"
# Open the CZI file and read a patch from the center
with czi.open_czi(path) as czidoc:
    bbox = czidoc.total bounding box
    x_{min}, x_{max} = bbox['X']
    y_min, y_max = bbox['Y']
    patch_size = 2048
    # Calculate the center coordinates
    center x = (x \min + x \max) / / 2
    center_y = (y_min + y_max) // 2
    # Calculate ROI coordinates
    roi_x = center_x - patch_size // 2
    roi_y = center_y - patch_size // 2
    # Read the patch at full resolution
    patch = czidoc.read(
        roi=(roi_x, roi_y, patch_size, patch_size),
        zoom=1.0 # Render at full (40%) resolution
    )
```

Figure 10: Python code demonstrating how to extract a tile from the centre of a WSI using in Python 3.8.13 and pylibCZIrw v4.1.3. This example illustrates how to interact with high-resolution pathology images in CZI format. This method can be easily expanded to tessellate over an entire whole slide image for the purpose of patch-level feature extraction.

2.9 Data re-use potential

The SurGen dataset offers extensive opportunities for researchers in computational pathology and oncology. Its comprehensive collection of WSIs, coupled with genetic and other clinical annotations, makes it a valuable resource for various applications.

Firstly, the dataset can be utilised to train machine learning models for predicting mismatch repair (MMR) status and microsatellite instability (MSI). Given that existing publicly available datasets focusing on MSI/MMR prediction are limited, SurGen fills a crucial gap. Researchers can leverage this dataset to develop and validate models that may enhance diagnostic accuracy and inform treatment strategies, particularly in colorectal cancer where MSI status is a key prognostic and therapeutic marker.

Secondly, SurGen provides a rich resource for training models aimed at genomic mutation prediction, specifically for mutations in the KRAS, NRAS, and BRAF genes. Expanding the quantity of publicly available datasets with such detailed genetic information is immensely valuable, as it enables the development of models that can predict genetic mutations from histopathological images. This can potentially streamline the diagnostic process by reducing the need for costly and time-consuming genetic testing.

Furthermore, the high-quality WSIs in the SurGen dataset make it suitable for training foundation models in digital pathology. Existing works have demonstrated that the performance of these models improves with the availability of




Figure 11: Example 2048 × 2048 pixel tile extracted from the centre of a whole slide image (WSI) using pylibCZIrw. This patch, from case SR1482_T232, illustrates the fine detail captured at 40X (0.1112 μ m per pixel) resolution. Extraction of patches, as demonstrated here, is an essential step in SOTA preprocessing pipelines.

larger and more diverse datasets [44–46]. By contributing to the training of such models, SurGen can aid in advancing the field of computational pathology, facilitating the development of algorithms that are more robust and generalisable. The dataset's versatility allows it to be used in multiple ways:

- Researchers may choose to utilise the SR386 or SR1482 subsets independently, depending on their specific research questions. For instance, studies focusing on primary tumour characteristics and survival can benefit from the SR386 cohort's valuable genetic and survival data.
- Alternatively, the entire SurGen dataset can be employed collectively as a larger cohort for tasks such as staging or genetic slide-level classification, benefiting from the increased sample size and additional diversity from metastatic tumour sites.
- SurGen also holds significant potential as an external validation set for existing studies and algorithms. External validation is essential for assessing the generalisability of predictive models, and the dataset's comprehensive annotations make it particularly suitable for this purpose [47].

To support systematic benchmarking and methodological comparisons, we provide example stratified data-splits for the SR386 subset (see Table 4), as well as for the SR1482 subset and the combined SurGen dataset. Although detailed stratifications are only presented here for SR386, equivalent splits for the full SurGen dataset and the SR1482 subset are available in the accompanying GitHub repository. Each split is stratified to ensure balanced distributions of key variables such as genetic mutations, MMR/MSI status, and survival metrics. These data partitions establish a standardised, transparent framework for evaluating model performance and reproducibility when utilising the SurGen dataset. An example of the dataset's utility is demonstrated in a study that explored the feasibility of digital pathology foundation models on the SR386 cohort. Using the UNI model [44], which was benchmarked against various other pathology-pretrained foundation models and an ImageNet-pretrained ResNet-50 [48], this work achieved a test AUROC of 0.7136 for slide-level classification of MMR status [49]. This underscores the dataset's potential in facilitating advanced machine learning applications.

3 Analyses

To further demonstrate the utility of the SurGen dataset, we conducted an experiment combining the SR386 and SR1482 cohorts to predict MMR status using a machine learning model. We utilised the existing training, validation, and test splits from each cohort and merged them to form unified training, validation, and test sets. This approach ensured that the combined SurGen dataset adhered to the 60:20:20 ratio for training, validation, and testing, respectively, while maintaining a balanced representation of mutation statuses across each split. By leveraging the predefined splits from both cohorts, we eliminated the need to generate a separate third split. The splits used in this experiment are provided in CSV format to ensure reproducibility.

Category	Total (SR386)	Train	Validate	Test
Origin	Scotland	Scotland	Scotland	Scotland
WSI file format	CZI	CZI	CZI	CZI
Magnification	×40	×40	×40	×40
Microns per pixel (pixel width)	0.1112µm	0.1112µm	0.1112µm	0.1112µm
Number of patients	423 (100%)	255 (60%)	84 (20%)	84 (20%)
Mean age at diagnosis (std. dev.)	67.89 (±11.97)	67.98 (±12.12)	67.71 (±11.40)	67.80 (±12.20)
Male, n (%)	228 (54%)	138 (54.1%)	46 (54.7%)	44 (52.3%)
Female, n (%)	195 (46.0%)	117 (45.8%)	38 (45.2%)	40 (47.6%)
MSS/pMMR, n (%)	391 (92%)	235 (92%)	78 (93%)	78 (93%)
MSI/dMMR, n (%)	32 (8%)	20 (8%)	6 (7%)	6 (7%)
Five year survival (true), n (%)	159 (38%)	100 (39%)	30 (36%)	29 (35%)
Five year survival (false), n (%)	264 (62%)	155 (61%)	54 (64%)	55 (65%)
RAS mutation, n (%)	158 (37%)	97 (38%)	31 (37%)	30 (36%)
RAS wild type, n (%)	265 (63%)	158 (62%)	53 (63%)	54 (64%)
BRAF mutation, n (%)	47 (11.1%)	29 (11.4%)	9 (10.7%)	9 (10.7%)
BRAF wild type, n (%)	375 (88.6%)	225 (88.2%)	75 (89.2%)	75 (89.2%)
BRAF fail, n (%)	1 (0.2%)	1 (0.4%)	0 (0%)	0 (0%)

Table 4: Breakdown of SR386 SurGen Colorectal Cohort data distribution for train, validate, and test sets. This stratification may act as an effective starting point for future analysis. Each patient has precisely one associated whole slide image. This breakdown was stratified by age, sex, MSI/MMR, RAS (KRAS or NRAS), and BRAF mutation.

3.1 Feature Extraction

A range of pre-trained foundation models have been developed for histopathological image analysis, each leveraging diverse self-supervised learning techniques and trained on extensive collections of WSIs. These models have demonstrated considerable success in capturing nuanced histopathological features [44, 50–71].

For this study, we employed the UNI foundation model [44] for feature extraction from WSIs. UNI was selected due to its robust performance in representing histopathological features relevant to microsatellite instability (MMR status) within the SR386 cohort [49]. The model is a self-supervised vision encoder trained on over 100,000 H&E-stained WSIs across a wide variety of tumour sites, thereby providing a comprehensive understanding of tissue morphology. Feature extraction was performed on non-overlapping 224x224 tissue patches at a scale of 1.0 microns per pixel (MPP), yielding a 1024-dimensional embedding for each patch. Background subtraction was applied as illustrated in Figure 12. The entire process of patch extraction and feature embedding required 110.55 hours, utilising a single NVIDIA V100 32GB GPU.

3.2 Model Training and Evaluation

A Transformer [72] based classifier was trained using the extracted UNI patch embeddings. Details of the model parameters are provided in Table 5. Performance was evaluated primarily using the Area Under the Receiver Operating Characteristic curve (AUROC) metric. Training was conducted on a single NVIDIA V100 32GB GPU, completing in 2 hours, 59 minutes, and 8 seconds. The progression of the training and validation AUROC, as well as the loss over 200 epochs, is shown in Figure 13. This figure highlights key performance metrics, including the highest validation AUROC and the lowest validation loss. Preliminary results indicate a validation AUROC of 0.9191 and a test AUROC of 0.8316 (see Figure 14 for test AUROC curve). These results demonstrate the model's potential for accurately predicting MMR status from WSIs. Future work could focus on fine-tuning hyperparameters and exploring the integration of state-of-the-art (SOTA) pretrained feature extractors to further improve model performance.

3.2.1 Model Architecture

The model consists of a feature embedding layer, a transformer encoder, an aggregation layer, and a classification head. The feature extractor used was the UNI model, which produced 1024-dimensional feature vectors for each patch. These were mapped to a 512-dimensional latent space via a fully connected layer and ReLU activation. The transformer encoder consisted of 2 layers, each with 2 attention heads, and a feedforward dimension of 2048. After passing through the transformer encoder, the patch features were mean-pooled to obtain a slide-level feature representation. A final fully connected layer then mapped the pooled feature vector to the number of classes (for multi-class tasks) or to a single output (for binary classification). The full architecture configuration is detailed in table 5.




Figure 12: Background subtraction from a) case SR148_T230, peritoneal biopsy and b) case SR148_T412, small bowel resection. Tissue area is circled in green with holes and background is highlighted in red.

3.2.2 Training Configuration

The model was trained using patch embeddings extracted from WSIs at $1.0\mu/pixel$ per pixel, with patch sizes of 224x224. As the number of patches per WSI varied based on the specimen size, we processed all patches in a single forward pass. The training was conducted on a single NVIDIA V100 32GB GPU, with a batch size of 1 and a learning rate of 1×10^{-4} . The Adam optimiser was used, and binary cross-entropy with logits loss (BCEWithLogitsLoss) was applied for binary classification tasks. No class balancing was performed. The model was trained for 200 epochs, and automatic mixed precision (AMP) was enabled to optimise GPU usage. Table 5 provides a summary of the key parameters used in the training process.

Parameter	Value
Task	MMR/MSI Detection
Cohort	SurGen
Feature Extractor	UNI
Patch Size	224x224
Microns per Pixel (MPP)	1.0
Embedding Dimension (d_{model})	512
Transformer Encoder Layers (<i>L</i>)	2
Attention Heads (H)	2
Feedforward Dimension $(d_{\rm ff})$	2048
Activation Function	ReLU
Dropout Rate	0.15
Layer Norm Epsilon	1×10^{-5}
Loss Function	BCEWithLogitsLoss
Optimiser	Adam
Learning Rate	1×10^{-4}
Batch Size	1
Epochs	200
Automatic Mixed Precision (AMP)	True
GPU	NVIDIA V100 32GB

Table 5: Summary of model parameters used for MMR/MSI classification.

3.3 Experiment Results

The results underscore the strong utility of the SurGen dataset for developing predictive models in computational pathology. Compared with the previous work[49], which achieved a 0.7136 AUROC on the smaller SR386 subset, the higher AUROC of 0.8316 observed here suggests that SurGen's broader scope and consistently high-quality images may foster more robust model performance. Although additional investigation is necessary to establish whether this improvement stems primarily from the expanded sample size, and greater tumour heterogeneity, these findings emphasise the importance of a large, well-curated dataset for accurate MMR status prediction.

The Transformer-based model demonstrated strong performance in predicting MMR status, achieving an AUROC of 0.9191 on the validation set and 0.8316 on the test set. To illustrate how well the model balances sensitivity and specificity, Figure 15 shows the confusion matrices at four thresholds, optimal (0.0139), 0.25, 0.50, and 0.75, providing a detailed breakdown of the model's classification performance. These matrices help reveal trade-offs between true positives and false positives under different decision criteria and indicate how threshold selection can be tailored for particular clinical aims. For instance, the 0.0139 threshold achieves 95% sensitivity on the validation set, which may be important in early-stage colorectal cancer to minimise the chance of missing diseased cases.

4 Discussion

In this study, we introduce the SurGen dataset, a comprehensive collection of 1020 H&E stained WSIs from 843 colorectal cancer cases with detailed genetic and clinical annotations. This dataset addresses the critical need for extensive, high-quality datasets in computational pathology to advance cancer diagnosis and treatment. To demonstrate its utility, we developed a machine learning model capable of predicting mismatch repair (MMR) status from the SurGen dataset, achieving a test AUROC of 0.8316 with no hyperparameter tuning. This performance demonstrates a significant improvement over previous efforts which, despite extensive hyperparameter optimisation on the SR386 subset, achieved an AUROC of only 0.7136 [49]. This further motivates the need for large and comprehensive WSI datasets to conduct robust and generalisable computational pathology research. The SurGen dataset directly addresses this need by providing a resource that complements existing datasets with its high-resolution WSIs, extensive annotations, and consistent imaging quality.

Unlike many existing datasets, which often suffer from inconsistent image quality which results in users removing subsets of cases [5, 73–76], SurGen offers over 1000 consistently high-quality WSIs. This ensures researchers can develop and evaluate models on a dataset that reflects real-world high-quality diagnostic conditions.




Figure 13: Train/Validation AUROC and Loss by Epoch: a) illustrates the train and validation AUROC progression over 200 epochs, with markers indicating the highest validation AUROC and the epoch with the lowest validation loss. b) shows the train and validation loss on a log scale, highlighting the convergence and divergence trends, with markers indicating key performance metrics such as the lowest validation loss and the epoch with the highest AUROC.





Figure 14: Receiver Operating Characteristic (ROC) curve for the model, showing an AUROC of 0.8316. The curve plots the true positive rate (sensitivity) against the false positive rate (1 - specificity) across various classification thresholds, with an AUROC of 1 representing perfect classification and 0.5 indicating random chance.



Test Set Confusion Matrices (Counts and Percentages) at Different Thresholds

Figure 15: Confusion matrices for mismatch repair (MMR) status prediction at various classification thresholds on the test set. The confusion matrices show the classification results for mismatch repair (MMR) status prediction across four different decision thresholds (0.0139, 0.25, 0.50, and 0.75). Threshold 0.0139 represents the point at which 95% sensitivity on validation set is reached. Each matrix shows the number and percentage of correct and incorrect predictions for the microsatellite-stable/proficient MMR (MSS/pMMR) and microsatellite-instable/deficient MMR (MSI/dMMR) classes.

The SurGen dataset's extensive annotations and high-quality WSIs make it a valuable resource for developing foundational AI models, enabling transfer learning and domain-specific fine-tuning across a wide range of computational pathology tasks.

By providing a robust foundation for algorithm development, the SurGen dataset supports ongoing efforts to personalise cancer diagnosis and treatment strategies at a global scale.

5 Potential implications

The SurGen dataset has the potential to impact various areas of cancer research and computational pathology.

In computational pathology, the dataset could serve as a valuable resource for developing and testing new algorithms, such as those utilising artificial intelligence and machine learning. The diversity of tumour sites and genetic annotations could help in creating more generalisable and robust models. Additional research could be developed with the aim of exploring the clinical tabular data with respect to tumour staging, genetic mutation, and survival analysis. Further work could aim to integrate all of these aspects on top of a computer vision model.

While the dataset originates from a single geographical region, it offers an opportunity to study population-specific cancer characteristics. Comparing SurGen with datasets from other regions might help identify global cancer disparities and inform international research. SurGen, in combination with other international datasets, may offer a broad and comprehensive resource that enhances the generalisability of computational models across diverse populations. This integration can facilitate the development of more robust diagnostic tools that are effective in varied clinical settings, ultimately contributing to a more unified and global approach to cancer diagnosis and treatment. Additionally, leveraging SurGen alongside other datasets can support large-scale studies, enabling researchers to validate findings across different cohorts and improve the reliability of predictive models. Such efforts can drive advancements in personalised medicine, ensuring that computational pathology solutions are both accurate and universally applicable.

Ultimately, the SurGen dataset has the potential to accelerate innovations in cancer diagnostics, enhance treatment personalisation, and contribute to reducing the global burden of colorectal cancer.

6 Availability of source code and requirements

Source code for data-processing and stratification, background subtraction, feature extraction, model training, and evaluation is available via https://github.com/CraigMyles/SurGen-Dataset

- Project name: SurGen-Dataset
- Project home page: https://github.com/CraigMyles/SurGen-Dataset
- Operating System: Ubuntu 20.04 LTS
- Programming language: Python
- Other requirements: Pytorch, pylibCZIrw, pandas, NumPy
- License: GPL-3.0 license

7 Data availability

The dataset supporting this article is available in the European Molecular Biology Laboratory European Bioinformatics Institute (EMBL-EBI) BioImage Archive repository [77]; available via the following link https://doi.org/10.6019/S-BIAD1285

Patch embeddings generated during the preprocessing stages using the UNI foundation model have also been made available to reduce the barrier for entry to researchers wishing to utilise this dataset; available via the following link https://doi.org/10.5281/zenodo.14047723

8 Compute Resource

In accordance with the recommended minimum documentation for computation time reporting [78], we have detailed the hardware specifications, computation time, and operating system used during the experiments.

Feature extraction from WSIs using the UNI foundation model took 2 days, 10 hours, 12 minutes, and 35 seconds on a system equipped with Dual 20-Core Intel Xeon E5-2698 v4 2.2 GHz and a single NVIDIA Tesla V100 32GB GPU. Model training was completed in 2 hours, 59 minutes, and 8 seconds under the same hardware conditions.

- System: NVIDIA DGX-1
- Operating System: Ubuntu 20.04 LTS
- CPU: Dual 20-Core Intel Xeon E5-2698 v4 2.2 GHz
- GPU: NVIDIA Tesla V100 32GB (Utilised 1 of 8 available)
- RAM: 512 GB DDR4 RAM

9 Declarations

9.1 List of abbreviations

AUROC: Area Under the Receiver Operating Characteristic; BRAF: v-Raf Murine Sarcoma Viral Oncogene Homolog B; CRC: Colorectal Cancer; CZI: Carl Zeiss Image (file format); dMMR: Deficient Mismatch Repair; FFPE: Formalin-Fixed Paraffin-Embedded; H&E: Hematoxylin and Eosin; IHC: Immunohistochemistry; KRAS: Kirsten Rat Sarcoma Viral Oncogene Homolog; MMR: Mismatch Repair; MSI: Microsatellite Instability; MSS: Microsatellite Stable; NGS: Next Generation Sequencing; NRAS: Neuroblastoma RAS Viral Oncogene Homolog; PCR: Polymerase Chain Reaction; TNM: Tumour, Node, Metastasis; WSI: Whole Slide Image;

9.2 Ethical Approval

Ethical approval has been granted by University of St Andrews School of Computer Science Ethics Committee; approval code CS16553. Additionally, Lothian NRS BioResource RTB approval (REC ref – 20/ES/0061 & 13/ES/0126) has been granted.

9.3 Consent for publication

This manuscript does not contain any individual person's data in a form that would require explicit consent for publication. Comprehensive efforts have been made to ensure patient anonymity. Identifiable information, such as dates of diagnosis, treatment details, and other specifics that could link specimens back to individual patients, have been removed. Furthermore, the dataset has undergone rigorous deidentification processes to aid the prevention re-identification.

9.4 Funding

CM is supported by NHS Lothian. The authors would like to thank NHS Lothian for providing tissue specimen. This work is supported in part by the Industrial Centre for AI Research in Digital Diagnostics (iCAIRD) which is funded by Innovate UK on behalf of UK Research and Innovation (UKRI) (project number 104690).

10 Acknowledgements

The authors would like to thank NHS Lothian for supporting this research and NHS Lothian Biorepository for providing tissue specimens. Special thanks to The Harrison Lab team for their dedicated work in slide processing, digitisation, and genetic and biomarker testing. We also acknowledge the MedTech team in the School of Computer Science at the University of St Andrews for their valuable feedback and support throughout this project.

References

- Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, and Freddie Bray. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, 71(3):209–249, 2021.
- [2] Freddie Bray, Mathieu Laversanne, Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Isabelle Soerjomataram, and Ahmedin Jemal. Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, 74(3):229–263, 2024.
- [3] Kaustav Bera, Kurt A Schalper, David L Rimm, Vamsidhar Velcheti, and Anant Madabhushi. Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology. *Nature reviews Clinical oncology*, 16(11): 703–715, 2019.
- [4] Muhammad Khalid Khan Niazi, Anil V Parwani, and Metin N Gurcan. Digital pathology and artificial intelligence. *The lancet oncology*, 20(5):e253–e261, 2019.
- [5] Esther Abels, Liron Pantanowitz, Famke Aeffner, Mark D Zarella, Jeroen Van der Laak, Marilyn M Bui, Venkata NP Vemuri, Anil V Parwani, Jeff Gibbs, Emmanuel Agosto-Arroyo, et al. Computational pathology definitions, best practices, and recommendations for regulatory guidance: a white paper from the digital pathology association. *The Journal of pathology*, 249(3):286–294, 2019.
- [6] Geert Litjens, Peter Bandi, Babak Ehteshami Bejnordi, Oscar Geessink, Maschenka Balkenhol, Peter Bult, Altuna Halilovic, Meyke Hermsen, Rob Van de Loo, Rob Vogels, et al. 1399 h&e-stained sentinel lymph node sections of breast cancer patients: the camelyon dataset. *GigaScience*, 7(6):giy065, 2018.
- [7] Fabio A Spanhol, Luiz S Oliveira, Caroline Petitjean, and Laurent Heutte. A dataset for breast cancer histopathological image classification. *Ieee transactions on biomedical engineering*, 63(7):1455–1462, 2015.
- [8] National Cancer Institute Clinical Proteomic Tumor Analysis Consortium et al. The clinical proteomic tumor analysis consortium breast invasive carcinoma collection (cptac-brca). *The Cancer Imaging Archive*, 2020.
- [9] Qian Da, Xiaodi Huang, Zhongyu Li, Yanfei Zuo, Chenbin Zhang, Jingxin Liu, Wen Chen, Jiahui Li, Dou Xu, Zhiqiang Hu, et al. Digestpath: A benchmark dataset with challenge review for the pathological detection and segmentation of digestive-system. *Medical Image Analysis*, 80:102485, 2022.
- [10] Kyungmo Kim, Kyoungbun Lee, Sungduk Cho, Dong Un Kang, Seongkeun Park, Yunsook Kang, Hyunjeong Kim, Gheeyoung Choe, Kyung Chul Moon, Kyu Sang Lee, et al. Paip 2020: Microsatellite instability prediction in colorectal cancer. *Medical Image Analysis*, 89:102886, 2023.
- [11] National Cancer Institute Clinical Proteomic Tumor Analysis Consortium et al. The clinical proteomic tumor analysis consortium lung adenocarcinoma collection (cptac-luad). *The Cancer Imaging Archive*, 2018.
- [12] Fortunato Ciardiello, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Josep Tabernero, and Andres Cervantes. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA: a cancer journal for clinicians, 72(4):372–401, 2022.
- [13] John N Weinstein, Eric A Collisson, Gordon B Mills, Kenna R Shaw, Brad A Ozenberger, Kyle Ellrott, Ilya Shmulevich, Chris Sander, and Joshua M Stuart. The cancer genome atlas pan-cancer analysis project. *Nature* genetics, 45(10):1113–1120, 2013.
- [14] National Cancer Institute Clinical Proteomic Tumor Analysis Consortium (CPTAC). The clinical proteomic tumor analysis consortium colon adenocarcinoma collection (cptac-coad), 2020. URL https://doi.org/10.7937/ TCIA.YZWQ-ZZ63.
- [15] Jeremiah Wala, Ino de Bruijn, Shannon Coy, Andreanne Gagne, Sabrina Chan, Yu-An Chen, John Hoffer, Jeremy Muhlich, Nikolaus Schultz, Sandro Santagata, et al. Integrating spatial profiles and cancer genomics to identify immune-infiltrated mismatch repair proficient colorectal cancers. *bioRxiv*, pages 2024–09, 2024.
- [16] Shuji Ogino, Takako Kawasaki, Gregory J Kirkner, Peter Kraft, Massimo Loda, and Charles S Fuchs. Evaluation of markers for cpg island methylator phenotype (cimp) in colorectal cancer by a large population-based sample. *The Journal of molecular diagnostics*, 9(3):305–314, 2007.
- [17] Zohreh Mirzapoor Abbasabadi, Dariush Hamedi Asl, Babak Rahmani, Rozhin Shahbadori, Sara Karami, Amir Peymani, Sara Taghizadeh, and Fatemeh Samiee Rad. Kras, nras, braf, and pik3ca mutation rates, clinicopathological association, and their prognostic value in iranian colorectal cancer patients. *Journal of clinical laboratory analysis*, 37(5):e24868, 2023.
- [18] Tian-An Guo, Yu-Chen Wu, Cong Tan, Yu-Tong Jin, Wei-Qi Sheng, San-Jun Cai, Fang-Qi Liu, and Ye Xu. Clinicopathologic features and prognostic value of kras, nras and braf mutations and dna mismatch repair status: a

single-center retrospective study of 1,834 chinese patients with stage i-iv colorectal cancer. *International journal of cancer*, 145(6):1625–1634, 2019.

- [19] Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans, George Fountzilas, Konstantine T Kalogeras, Vassiliki Kotoula, Demetris Papamichael, Pierre Laurent-Puig, et al. Effects of kras, braf, nras, and pik3ca mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *The lancet oncology*, 11(8):753–762, 2010.
- [20] Francesco Sclafani, Sanna Hulkki Wilson, David Cunningham, David Gonzalez De Castro, Eleftheria Kalaitzaki, Ruwaida Begum, Andrew Wotherspoon, Jaume Capdevila, Bengt Glimelius, Susana Roselló, et al. Analysis of kras, nras, braf, pik3ca and tp53 mutations in a large prospective series of locally advanced rectal cancer patients. *International Journal of Cancer*, 146(1):94–102, 2020.
- [21] Mauricio Burotto, Victoria L Chiou, Jung-Min Lee, and Elise C Kohn. The mapk pathway across different malignancies: a new perspective. *Cancer*, 120(22):3446–3456, 2014.
- [22] Jack McCain. The mapk (erk) pathway: investigational combinations for the treatment of braf-mutated metastatic melanoma. *Pharmacy and Therapeutics*, 38(2):96, 2013.
- [23] Zi-Nan Li, Lin Zhao, Li-Feng Yu, and Min-Jie Wei. Braf and kras mutations in metastatic colorectal cancer: future perspectives for personalized therapy. *Gastroenterology report*, 8(3):192–205, 2020.
- [24] C Richard Boland and Ajay Goel. Microsatellite instability in colorectal cancer. *Gastroenterology*, 138(6): 2073–2087, 2010.
- [25] Eduardo Vilar and Stephen B Gruber. Microsatellite instability in colorectal cancer—the stable evidence. *Nature reviews Clinical oncology*, 7(3):153–162, 2010.
- [26] Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber, et al. Mismatch repair deficiency predicts response of solid tumors to pd-1 blockade. *Science*, 357(6349):409–413, 2017.
- [27] C Luchini, F Bibeau, MJL Ligtenberg, Navdeep Singh, A Nottegar, T Bosse, R Miller, N Riaz, J-Y Douillard, F Andre, et al. Esmo recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with pd-1/pd-11 expression and tumour mutational burden: a systematic review-based approach. *Annals of Oncology*, 30(8):1232–1243, 2019.
- [28] Henry T Lynch, PM Lynch, SJ Lanspa, CL Snyder, JF Lynch, and CR Boland. Review of the lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. *Clinical genetics*, 76 (1):1–18, 2009.
- [29] Ashish K Tiwari, Hemant K Roy, and HT Lynch. Lynch syndrome in the 21st century: clinical perspectives. *QJM: An International Journal of Medicine*, 109(3):151–158, 2016.
- [30] Heather Hampel, Wendy L Frankel, Edward Martin, Mark Arnold, Karamjit Khanduja, Philip Kuebler, Hidewaki Nakagawa, Kaisa Sotamaa, Thomas W Prior, Judith Westman, et al. Screening for the lynch syndrome (hereditary nonpolyposis colorectal cancer). New England Journal of Medicine, 352(18):1851–1860, 2005.
- [31] Henry T Lynch, Jane F Lynch, Patrick M Lynch, and Thomas Attard. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. *Familial cancer*, 7:27–39, 2008.
- [32] Mahul B Amin, Frederick L Greene, Stephen B Edge, Carolyn C Compton, Jeffrey E Gershenwald, Robert K Brookland, Laura Meyer, Donna M Gress, David R Byrd, and David P Winchester. The eighth edition ajcc cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. *CA: a cancer journal for clinicians*, 67(2):93–99, 2017.
- [33] Cuthbert E Dukes. The classification of cancer of the rectum. *The Journal of Pathology and Bacteriology*, 35(3): 323–332, 1932.
- [34] International Union against Cancer. Committee on TNM Classification. *TNM classification of malignant tumours*. International Union Against Cancer, 1974.
- [35] Asif I Haq, Jenifer Schneeweiss, Vinay Kalsi, and Manit Arya. The dukes staging system: a cornerstone in the clinical management of colorectal cancer. *The lancet oncology*, 10(11):1128, 2009.
- [36] Leslie H Sobin, Mary K Gospodarowicz, and Christian Wittekind. *TNM classification of malignant tumours*. John Wiley & Sons, 2011.
- [37] Petr Holub, Heimo Müller, Tomáš Bíl, Luca Pireddu, Markus Plass, Fabian Prasser, Irene Schlünder, Kurt Zatloukal, Rudolf Nenutil, and Tomáš Brázdil. Privacy risks of whole-slide image sharing in digital pathology. *Nature Communications*, 14(1):2577, 2023.

- [38] Adam Goode, Benjamin Gilbert, Jan Harkes, Drazen Jukic, and Mahadev Satyanarayanan. Openslide: A vendor-neutral software foundation for digital pathology. *Journal of pathology informatics*, 4(1):27, 2013.
- [39] ZEISS. pylibczirw: A Python wrapper for libCZI. https://github.com/ZEISS/pylibczirw, 2024. Commit ID: 264fcb4ab95274e54433a0054d69f07c402582f4.
- [40] Josh Moore, Melissa Linkert, Colin Blackburn, Mark Carroll, Richard K Ferguson, Helen Flynn, Kenneth Gillen, Roger Leigh, Simon Li, Dominik Lindner, et al. Omero and bio-formats 5: flexible access to large bioimaging datasets at scale. In *Medical Imaging 2015: Image Processing*, volume 9413, pages 37–42. SPIE, 2015.
- [41] Peter Bankhead, Maurice B Loughrey, José A Fernández, Yvonne Dombrowski, Darragh G McArt, Philip D Dunne, Stephen McQuaid, Ronan T Gray, Liam J Murray, Helen G Coleman, et al. Qupath: Open source software for digital pathology image analysis. *Scientific reports*, 7(1):1–7, 2017.
- [42] Johannes Schindelin, Ignacio Arganda-Carreras, Erwin Frise, Verena Kaynig, Mark Longair, Tobias Pietzsch, Stephan Preibisch, Curtis Rueden, Stephan Saalfeld, Benjamin Schmid, et al. Fiji: an open-source platform for biological-image analysis. *Nature methods*, 9(7):676–682, 2012.
- [43] Caroline A Schneider, Wayne S Rasband, and Kevin W Eliceiri. Nih image to imagej: 25 years of image analysis. *Nature methods*, 9(7):671–675, 2012.
- [44] Richard J Chen, Tong Ding, Ming Y Lu, Drew FK Williamson, Guillaume Jaume, Andrew H Song, Bowen Chen, Andrew Zhang, Daniel Shao, Muhammad Shaban, et al. Towards a general-purpose foundation model for computational pathology. *Nature Medicine*, 30(3):850–862, 2024.
- [45] Maxime Oquab, Timothée Darcet, Théo Moutakanni, Huy Vo, Marc Szafraniec, Vasil Khalidov, Pierre Fernandez, Daniel Haziza, Francisco Massa, Alaaeldin El-Nouby, et al. Dinov2: Learning robust visual features without supervision. arXiv preprint arXiv:2304.07193, 2023.
- [46] Sara P Oliveira, Pedro C Neto, João Fraga, Diana Montezuma, Ana Monteiro, João Monteiro, Liliana Ribeiro, Sofia Gonçalves, Isabel M Pinto, and Jaime S Cardoso. Cad systems for colorectal cancer from wsi are still not ready for clinical acceptance. *Scientific Reports*, 11(1):14358, 2021.
- [47] Miao Cui and David Y Zhang. Artificial intelligence and computational pathology. *Laboratory Investigation*, 101 (4):412–422, 2021.
- [48] Kaiming He, Xiangyu Zhang, Shaoqing Ren, and Jian Sun. Deep residual learning for image recognition. In *Proceedings of the IEEE conference on computer vision and pattern recognition*, pages 770–778, 2016.
- [49] Craig Myles, In Hwa Um, David J Harrison, and David Harris-Birtill. Leveraging foundation models for enhanced detection of colorectal cancer biomarkers in small datasets. In *Annual Conference on Medical Image Understanding and Analysis*, pages 329–343. Springer, 2024.
- [50] Xiyue Wang, Sen Yang, Jun Zhang, Minghui Wang, Jing Zhang, Wei Yang, Junzhou Huang, and Xiao Han. Transformer-based unsupervised contrastive learning for histopathological image classification. *Medical image analysis*, 81:102559, 2022.
- [51] Shekoofeh Azizi, Laura Culp, Jan Freyberg, Basil Mustafa, Sebastien Baur, Simon Kornblith, Ting Chen, Nenad Tomasev, Jovana Mitrović, Patricia Strachan, et al. Robust and data-efficient generalization of self-supervised machine learning for diagnostic imaging. *Nature Biomedical Engineering*, 7(6):756–779, 2023.
- [52] Richard J Chen, Chengkuan Chen, Yicong Li, Tiffany Y Chen, Andrew D Trister, Rahul G Krishnan, and Faisal Mahmood. Scaling vision transformers to gigapixel images via hierarchical self-supervised learning. In Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition, pages 16144–16155, 2022.
- [53] Mingu Kang, Heon Song, Seonwook Park, Donggeun Yoo, and Sérgio Pereira. Benchmarking self-supervised learning on diverse pathology datasets. In *Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition*, pages 3344–3354, 2023.
- [54] Alexandre Filiot, Ridouane Ghermi, Antoine Olivier, Paul Jacob, Lucas Fidon, Alice Mac Kain, Charlie Saillard, and Jean-Baptiste Schiratti. Scaling self-supervised learning for histopathology with masked image modeling. *medRxiv*, pages 2023–07, 2023.
- [55] Ming Y Lu, Bowen Chen, Drew FK Williamson, Richard J Chen, Ivy Liang, Tong Ding, Guillaume Jaume, Igor Odintsov, Long Phi Le, Georg Gerber, et al. A visual-language foundation model for computational pathology. *Nature Medicine*, 30(3):863–874, 2024.
- [56] Eugene Vorontsov, Alican Bozkurt, Adam Casson, George Shaikovski, Michal Zelechowski, Kristen Severson, Eric Zimmermann, James Hall, Neil Tenenholtz, Nicolo Fusi, et al. A foundation model for clinical-grade computational pathology and rare cancers detection. *Nature medicine*, pages 1–12, 2024.

- [57] Gabriele Campanella, Ricky Kwan, Eugene Fluder, Jennifer Zeng, Aryeh Stock, Brandon Veremis, Alexandros D Polydorides, Cyrus Hedvat, Adam Schoenfeld, Chad Vanderbilt, et al. Computational pathology at health system scale–self-supervised foundation models from three billion images. arXiv preprint arXiv:2310.07033, 2023.
- [58] Jeremy Lai, Faruk Ahmed, Supriya Vijay, Tiam Jaroensri, Jessica Loo, Saurabh Vyawahare, Saloni Agarwal, Fayaz Jamil, Yossi Matias, Greg S Corrado, et al. Domain-specific optimization and diverse evaluation of self-supervised models for histopathology. *arXiv preprint arXiv:2310.13259*, 2023.
- [59] Shengyi Hua, Fang Yan, Tianle Shen, Lei Ma, and Xiaofan Zhang. Pathoduet: Foundation models for pathological slide analysis of h&e and ihc stains. *Medical Image Analysis*, 97:103289, 2024.
- [60] Jonas Dippel, Barbara Feulner, Tobias Winterhoff, Timo Milbich, Stephan Tietz, Simon Schallenberg, Gabriel Dernbach, Andreas Kunft, Simon Heinke, Marie-Lisa Eich, et al. Rudolfv: a foundation model by pathologists for pathologists. arXiv preprint arXiv:2401.04079, 2024.
- [61] Nanne Aben, Edwin D de Jong, Ioannis Gatopoulos, Nicolas Känzig, Mikhail Karasikov, Axel Lagré, Roman Moser, Joost van Doorn, Fei Tang, et al. Towards large-scale training of pathology foundation models. arXiv preprint arXiv:2404.15217, 2024.
- [62] Dinkar Juyal, Harshith Padigela, Chintan Shah, Daniel Shenker, Natalia Harguindeguy, Yi Liu, Blake Martin, Yibo Zhang, Michael Nercessian, Miles Markey, et al. Pluto: Pathology-universal transformer. arXiv preprint arXiv:2405.07905, 2024.
- [63] Zhaochang Yang, Ting Wei, Ying Liang, Xin Yuan, Ruitian Gao, Yujia Xia, Jie Zhou, Yue Zhang, and Zhangsheng Yu. A foundation model for generalizable cancer diagnosis and survival prediction from histopathological images. *bioRxiv*, pages 2024–05, 2024.
- [64] Hanwen Xu, Naoto Usuyama, Jaspreet Bagga, Sheng Zhang, Rajesh Rao, Tristan Naumann, Cliff Wong, Zelalem Gero, Javier González, Yu Gu, et al. A whole-slide foundation model for digital pathology from real-world data. *Nature*, pages 1–8, 2024.
- [65] Dmitry Nechaev, Alexey Pchelnikov, and Ekaterina Ivanova. Hibou: A family of foundational vision transformers for pathology. *arXiv preprint arXiv:2406.05074*, 2024.
- [66] Charlie Saillard, Rodolphe Jenatton, Felipe Llinares-López, Zelda Mariet, David Cahané, Eric Durand, and Jean-Philippe Vert. H-optimus-0, 2024. URL https://github.com/bioptimus/releases/tree/main/ models/h-optimus/v0.
- [67] Yingxue Xu, Yihui Wang, Fengtao Zhou, Jiabo Ma, Shu Yang, Huangjing Lin, Xin Wang, Jiguang Wang, Li Liang, Anjia Han, et al. A multimodal knowledge-enhanced whole-slide pathology foundation model. *arXiv preprint arXiv:2407.15362*, 2024.
- [68] Eric Zimmermann, Eugene Vorontsov, Julian Viret, Adam Casson, Michal Zelechowski, George Shaikovski, Neil Tenenholtz, James Hall, Thomas Fuchs, Nicolo Fusi, et al. Virchow 2: Scaling self-supervised mixed magnification models in pathology. arXiv preprint arXiv:2408.00738, 2024.
- [69] Alexandre Filiot, Paul Jacob, Alice Mac Kain, and Charlie Saillard. Phikon-v2, a large and public feature extractor for biomarker prediction. *arXiv preprint arXiv:2409.09173*, 2024.
- [70] Xiyue Wang, Junhan Zhao, Eliana Marostica, Wei Yuan, Jietian Jin, Jiayu Zhang, Ruijiang Li, Hongping Tang, Kanran Wang, Yu Li, et al. A pathology foundation model for cancer diagnosis and prognosis prediction. *Nature*, pages 1–9, 2024.
- [71] Tong Ding, Sophia J Wagner, Andrew H Song, Richard J Chen, Ming Y Lu, Andrew Zhang, Anurag J Vaidya, Guillaume Jaume, Muhammad Shaban, Ahrong Kim, et al. Multimodal whole slide foundation model for pathology. arXiv preprint arXiv:2411.19666, 2024.
- [72] Ashish Vaswani, Noam Shazeer, Niki Parmar, Jakob Uszkoreit, Llion Jones, Aidan N Gomez, Łukasz Kaiser, and Illia Polosukhin. Attention is all you need. 30, 2017.
- [73] Maryam Haghighat, Lisa Browning, Korsuk Sirinukunwattana, Stefano Malacrino, Nasullah Khalid Alham, Richard Colling, Ying Cui, Emad Rakha, Freddie C Hamdy, Clare Verrill, et al. Automated quality assessment of large digitised histology cohorts by artificial intelligence. *Scientific Reports*, 12(1):5002, 2022.
- [74] Hyun-Jong Jang, Ahwon Lee, J Kang, In Hye Song, and Sung Hak Lee. Prediction of clinically actionable genetic alterations from colorectal cancer histopathology images using deep learning. *World Journal of Gastroenterology*, 26(40):6207, 2020.
- [75] Maxime W Lafarge, Enric Domingo, Korsuk Sirinukunwattana, Ruby Wood, Leslie Samuel, Graeme Murray, Susan D Richman, Andrew Blake, David Sebag-Montefiore, Simon Gollins, et al. Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy. NPJ precision oncology, 8(1):89, 2024.

- [76] Hongming Xu, Yoon Jin Cha, Jean R Clemenceau, Jinhwan Choi, Sung Hak Lee, Jeonghyun Kang, and Tae Hyun Hwang. Spatial analysis of tumor-infiltrating lymphocytes in histological sections using deep learning techniques predicts survival in colorectal carcinoma. *The Journal of Pathology: Clinical Research*, 8(4):327–339, 2022.
- [77] Matthew Hartley, Gerard J Kleywegt, Ardan Patwardhan, Ugis Sarkans, Jason R Swedlow, and Alvis Brazma. The bioimage archive–building a home for life-sciences microscopy data. *Journal of Molecular Biology*, 434(11): 167505, 2022.
- [78] David Harris-Birtill and Rose Harris-Birtill. Understanding computation time: a critical discussion of time as a computational performance metric. In *Time in Variance*, pages 220–248. Brill, 2021.